FindTrial
Sign In

Levomilnacipran ER

DRUG8 trials

Sponsors

Forest Laboratories, Allergan

Conditions

DepressionDepressive Disorder, MajorMajor Depressive Disorder

Phase 2

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
CompletedNCT01254305
Forest LaboratoriesMajor Depressive Disorder
Start: 2011-04-30End: 2012-07-31Updated: 2014-08-06

Phase 3

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
CompletedNCT00969709
Forest LaboratoriesMajor Depressive Disorder
Start: 2009-09-30Updated: 2013-10-25
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
CompletedNCT00969150
Forest LaboratoriesMajor Depressive Disorder
Start: 2009-09-30Updated: 2013-10-25
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
CompletedNCT01034462
Forest LaboratoriesMajor Depressive Disorder
Start: 2009-12-31End: 2011-12-31Updated: 2013-10-25
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
CompletedNCT01085812
Forest LaboratoriesDepression, Major Depressive Disorder
Start: 2010-03-31End: 2011-10-31Updated: 2020-01-13
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
CompletedNCT01377194
Forest LaboratoriesMajor Depressive Disorder
Start: 2011-06-30End: 2012-03-31Updated: 2013-10-29
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
CompletedNCT03569475
AllerganMajor Depressive Disorder
Start: 2018-07-06End: 2021-03-01Updated: 2022-03-25

Phase 4

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
CompletedNCT02288325
Forest LaboratoriesDepressive Disorder, Major
Start: 2014-11-18End: 2016-09-16Updated: 2018-10-29

Related Papers

Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies
Journal of Child and Adolescent Psychopharmacology2024-05-035 citations
Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments
International Clinical Psychopharmacology2016-11-1811 citations
Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
International Clinical Psychopharmacology2016-07-2313 citations
The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
2015-12-303 citations
Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder
The Primary Care Companion For CNS Disorders2015-06-112 citations
Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
2014-09-108 citations
Higher Doses of Levomilnacipran May Benefit Patients with Severe Depression
MD Conference Express2014-06-01
A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
2014-01-1629 citations
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
Journal of Psychiatry and Neuroscience2014-01-0169 citations
A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
Journal of Clinical Psychopharmacology2013-10-3090 citations
Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
2013-03-0165 citations